---

Business of the House

Will the Leader of the House allow us to have a debate on access to drug treatment for sufferers of ultra-orphan conditions, which are extremely rare. Last March, the National Institute for Health and Clinical Excellence proposed that the Department of Health introduce different guidelines so that it could review those drugs, which are necessarily more expensive, as the costs are spread among fewer patients. Last year, however, the Department rejected the NICE proposal so that sufferers of rare conditions in Britain have no prospect of access to new treatment. May we have a debate, because that is not the right way to progress the issue?